Trial Profile
Effectiveness of Regorafenib in Italian patients with hormone-refractory metastatic castration-resistant prostate cancer (mCRPC)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 20 Mar 2018
Price :
$35
*
At a glance
- Drugs Regorafenib (Primary)
- Indications Colorectal cancer
- Focus Therapeutic Use
- 20 Mar 2018 New trial record